CoChat

A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin

Open access
Liutkus, J., Rosas Guzman, J., Norwood, P., Pop, L., Northrup, J., Cao, D., Trautmann, M. · 2010 · Diabetes, Obesity and Metabolism
Cited by 74

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Aim: To test the hypothesis that glycaemic control with exenatide added to thiazolidinediones (TZDs) with or without metformin was superior to placebo. Methods: A 26‐week, multi‐country (Canada, Mexico, Romania, South Africa and the USA), randomized, double‐blind, placebo‐controlled study compared exenatide twice‐daily vs. placebo in 165 subjects suboptimally controlled with TZDs with or without metformin [HbA 1c 8.2% (s.d. 0.9), fasting serum glucose 9.1 (2.6) mmol/l, body weight 93.9 (17.8) kg, diabetes duration 6.4 (4.3) years]. After a 2‐week, single‐blind, lead‐in period, subjects were randomly assigned (2 : 1) to add exenatide or placebo to current regimens. The primary endpoint was HbA 1c change at endpoint (Week 26 or last‐observation‐carried‐forward). Results: Only 8 subjects were treated with concomitant TZD alone. Exenatide reduced HbA 1c significantly more than placebo [−0.84% (s.e. 0.20) vs. −0.10% (0.23), treatment difference −0.74% (0.16), p < 0.001)]. Mean reductions in body weight were similar in both treatments at endpoint [exenatide, −1.4 (s.e. 0.6) kg vs. placebo, −0.8 (0.7) kg, p = 0.176)]. Nearly 71% of subjects had both a reduction in HbA 1c and body weight with exenatide compared with 54% with placebo. The most common adverse events (exenatide vs. placebo) were nausea (12% vs. 2%, p = 0.037), vomiting (8% vs. 0%, p = 0.031) and headache (4% vs. 4%). Confirmed (blood glucose <3.0 mmol/l) minor hypoglycaemia was experienced by 4 and 2% of subjects treated with exenatide and placebo, respectively. Incidence of hypoglycaemia was not significantly different between groups. Conclusions: Exenatide added to TZDs alone or in combination with metformin significantly improved glycaemic control as determined by significant improvement in HbA 1c without associated hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2010.01251.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 74

Metadata

Authors
Liutkus, J., Rosas Guzman, J., Norwood, P., Pop, L., Northrup, J., Cao, D., & Trautmann, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2010-10-26
Volume
12
Issue
12
Pages
1058-1065
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2066046508
Cited by
74
References
12
FWCI
6.60
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin. https://app.cochat.ai/papers/10.1111/j.1463-1326.2010.01251.x
The paper
Liutkus, J., Rosas Guzman, J., Norwood, P., Pop, L., Northrup, J., Cao, D., & Trautmann, M. (2010). A placebo‐controlled trial of exenatide twice‐daily added to thiazolidinediones alone or in combination with metformin. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2010.01251.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.